Hepregen Inc., a Winchester, Mass.-based company focused on reducing the liver toxicity of existing pharmaceuticals, has secured $3 million of a $5 million Series A round, according to a regulatory filing.
Hepregen Inc., a Winchester, Mass.-based company focused on reducing the liver toxicity of existing pharmaceuticals, has secured $3 million of a $5 million Series A round, according to a regulatory filing.
